GVHD Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.
Featured
Study findings showed that vedolizumab 300 mg was tolerable and led to low incidence of overall and lower-intestinal aGVHD in patients who undergo allo-HSCT.
View More